Still Waiting for Answers

Still Waiting for Answers

November 2, 2004

News

Article

Pharmaceutical TechnologyPharmaceutical Technology-11-02-2004

Volume 28

Issue 11

Amid the finger-pointing, hand-wringing, and bloviating, the supply of hard, technical information remains frustratingly small.

External Link - article-142150.pdf

Articles in this issue

Still Waiting for Answers

Method Validation by Phase of Development: An Acceptable Analytical Practice

Comparing and Contrasting Barrier Isolator Decontamination Systems

November 2004

In the Spotlight-November 2004

Searching for a Viable Business Model

Bringing Formulations to Size: Strategies for Micro- and Nanoparticle Development

FDA Moves To Implement New GMP Policies

Related Content

mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

Christopher Cole

June 12th 2025

Article

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas

June 25th 2024

Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

Patrick Lavery

June 11th 2025

Article

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

Patrick Lavery

June 10th 2025

Article

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.